Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism

PHASE4CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2010

Conditions
Major Depression
Interventions
OTHER

Open label pharmacotherapy

"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"

Trial Locations (1)

K1Z 7K4

University of Ottawa Institute of Mental Health Research, Ottawa

All Listed Sponsors
lead

University of Ottawa

OTHER

NCT00704860 - Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism | Biotech Hunter | Biotech Hunter